Attached files
file | filename |
---|---|
EX-10.2 - REGISTRATION RIGHTS AGREEMENT - Sunshine Biopharma, Inc | sbfm_ex102.htm |
EX-10.1 - EQUITY FINANCING AGREEMENT - Sunshine Biopharma, Inc | sbfm_ex101.htm |
EX-4.1 - PROMISSORY NOTE - Sunshine Biopharma, Inc | sbfm_ex41.htm |
8-K - CURRENT REPORT - Sunshine Biopharma, Inc | sbfm_8k.htm |
Exhibit 99.1
For Immediate Release
September 14, 2018
SUNSHINE BIOPHARMA ANNOUNCES $10 MILLION EQUITY
FINANCING
Montreal,
Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma,
Inc. (OTCMKTS: SBFM) (the “Company” or
“Sunshine”), a pharmaceutical company focused on the
research, development and commercialization of drugs for the
treatment of aggressive forms of cancer, today announced that it
has entered into an Equity Financing Agreement (“Equity
Financing Agreement”) and Registration Rights Agreement
(“Registration Rights Agreement”) with GHS Investments
LLC, a Nevada limited liability company (“GHS”). Under
the terms of the Equity Financing Agreement, GHS agreed to provide
Sunshine with up to $10,000,000 upon effectiveness of a
registration statement on Form S-1 (the “Registration
Statement”) filed with the U.S. Securities and Exchange
Commission.
Following
effectiveness of the Registration Statement, Sunshine will have the
right in its sole discretion to deliver puts to GHS and GHS will be
obligated to purchase shares of Sunshine’s Common Stock (the
“Common Stock”) based on the investment amount
specified in each put notice. The maximum amount that Sunshine is
entitled to put to GHS in each put notice shall not exceed 250% of
the average daily trading dollar volume of the Company’s
Common Stock during the 10 trading days preceding the put date, so
long as such amount does not exceed $300,000. Pursuant to the
Equity Financing Agreement, GHS and its affiliates will not be
permitted to purchase and the Company may not put shares of its
Common Stock to GHS that would result in GHS’s beneficial
ownership equaling more than 9.99% of the Company’s
outstanding Common Stock. The price of each put share shall be
equal to 81% of the average of the three lowest Volume-Weighted
Average Prices (VWAP) of the Company's Common Stock for the 10
trading days immediately preceding the put notice date. Puts may be
delivered by the Company to GHS until the earlier of 36 months
after the effectiveness of the Registration Statement or the date
on which GHS has purchased an aggregate of $10,000,000 worth of
Common Stock.
The
Equity Financing Agreement and the Registration Rights Agreement do
not impose any restrictions on Sunshine’s operating
activities.
About Sunshine Biopharma Inc.
Sunshine
Biopharma is pharmaceutical company focused on the research,
development and commercialization of drugs for the treatment of
aggressive forms of cancer. Sunshine Biopharma’s business
plan includes the clinical development of Adva-27a, the
Company’s proprietary anticancer compound. Tests conducted on
Adva-27a have demonstrated the drug’s effectiveness at
destroying Multidrug Resistant Cancer Cells including Pancreatic
Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells,
and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University’s
Jewish General Hospital in Montreal, Canada.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's
development, events conditioned on stockholder or other approval,
or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma, Inc.
Camille
Sebaaly, CFO
Direct
Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com